Chamian Francesca, Lin Shao-Lee, Lee Edmund, Kikuchi Toyoko, Gilleaudeau Patricia, Sullivan-Whalen Mary, Cardinale Irma, Khatcherian Artemis, Novitskaya Inna, Wittkowski Knut M, Krueger James G, Lowes Michelle A
Laboratory for Investigative Dermatology, The Rockefeller University, New York, USA.
J Transl Med. 2007 Jun 7;5:27. doi: 10.1186/1479-5876-5-27.
Alefacept (anti-CD2) biological therapy selectively targets effector memory T cells (Tem) in psoriasis vulgaris, a model Type 1 autoimmune disease.
Circulating leukocytes were phenotyped in patients receiving alefacept for moderate to severe psoriasis.
In all patients, this treatment caused a preferential decrease in effector memory T cells (CCR7- CD45RA-) (mean 63% reduction) for both CD4+ and CD8+ Tem, while central memory T cells (Tcm) (CCR7+CD45RA-) were less affected, and naïve T cells (CCR7+CD45RA+) were relatively spared. Circulating CD8+ effector T cells and Type 1 T cells (IFN-gamma-producing) were also significantly reduced.
Alefacept causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.
阿法赛特（抗CD2）生物疗法选择性地靶向寻常型银屑病（一种典型的1型自身免疫性疾病）中的效应记忆T细胞（Tem）。
对接受阿法赛特治疗中度至重度银屑病的患者的循环白细胞进行表型分析。
在所有患者中，这种治疗导致CD4 +和CD8 + Tem的效应记忆T细胞（CCR7 - CD45RA -）优先减少（平均减少63%），而中枢记忆T细胞（Tcm）（CCR7 + CD45RA -）受影响较小，初始T细胞（CCR7 + CD45RA +）相对未受影响。循环CD8 +效应T细胞和1型T细胞（产生干扰素-γ的细胞）也显著减少。
阿法赛特可使银屑病患者循环中的效应记忆T细胞（Tem）选择性减少，中枢记忆T细胞（Tcm）相对保留。
Zotero 插件